KROS-401

N/A

Report date: 2023/09/05 15:53:56
NME

Base Information

Drug NameKROS-401
Drug Alias NameKROS401
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionInterleukin-4 inhibitorsInterleukin-13 inhibitors
TargetsInterleukin-4Interleukin-13
Therapy Area/IndicationsFibrosisTriple Negative Breast NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCedars-Sinai Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCedars-Sinai Medical CenterKairos Pharma Ltd
Inactive CompaniesN/A
Active IndicationsFibrosisTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A